Anadys Pharmaceuticals Inc.
3115 Merryfield Row
San Diego,
CA 92121
United States - Map
Phone: 858-530-3600
Web Site: http://www.anadyspharma.com
| Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing medicines in the areas of hepatitis C and oncology. It develops ANA598, a small-molecule non-nucleoside inhibitor of the NS5B polymerase for the treatment of hepatitis C; and ANA773, an oral toll-like receptor 7 agonist prodrug for cancer. The company was founded in 1992. It was formerly known as ScripTech Pharmaceuticals, Inc. and changed its name to Scriptgen Pharmaceuticals, Inc. in 1994. Later, the company changed its name to Anadys Pharmaceuticals, Inc. in 2000. Anadys Pharmaceuticals is headquartered in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Stephen T. Worland Ph.D., 50
Chief Exec. Officer, Pres, Director and Member of Strategic Committee |
$
461.00K |
$
45.00K | Dr. Stelios Papadopoulos Ph.D., 59
Co-Founder, Independent Director and Member of Corp. Governance & Nominating Committee |
$
18.00K | N/A | Mr. James T. Glover , 58
Chief Financial Officer, Principal Accounting Officer and Sr. VP of Operations |
$
370.00K | N/A | Dr. Devron Averett Ph.D., 58
Chief Scientific Counsel and Member of Clinical & Scientific Advisory Board |
$
189.00K |
$
16.00K | Dr. James L. Freddo M.D., 53
Chief Medical Officer |
$
450.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
2.09% Nasdaq 
0.12 (6.11%) 
Profile
